1-855-378-42281-855-378-4228
One of the out-patient treatment options for clients in Callicoon Center battling with opioid abuse and addiction is called opioid maintenance therapy. Some facilities and doctors are authorized to administer specific meds to opioid addicted people, many that are opioids themselves and are addiction. With low enough doses however, the client doesn't experience being high and also does not experience severe cravings and is not in opioid withdrawal. Methadone is the first drug administered for this sole purpose, but there are other choices to select from.
Methadone is an opioid and is meant to be taken at an outpatient medical center licensed to administer the drug, which is taken daily as a pill or liquid. The cost of the med is about $150 per month. Buprenorphine is also an opioid based med, and is in pill form often taken one day on, one day off. But different from Methadone that is only be dispensed in highly structured clinics, Buprenorphine can be and is prescribed and dispensed in doctor's offices. The monthly cost of buprenorphine is approximately just under $300 per month for the generic version of the drug. There is also a version of buprenorphine that contains the ingredient naloxone, which is a med that reverses the effects of opioids. Someone taking this formulation, AKA Suboxone, would find it more difficult to get high from opioids if they relapsed while taking the drug. It too is taken on a daily basis, and is priced around $450 monthly. Naltrexone is an additional med used in opioid maintenance therapy, but unlike the other medications aforementioned it's an opiate blocker and isn't an opioid. A person has the choice to take this medication as a monthly injection, which is called Vivitrol. As an opioid blocker, the drug prevents someone from experience high feelings from opioids, and in turn lowers the risk associated with relapse. This daily shot costs anywhere from $1000 to $1200 a month.
For All Drug and Alcohol Rehabilitation Programs In Callicoon Center, Click Here.
